Evolent Health (EVH)

• Market cap: $1.45B
• 1 day: -0.63%
• 5 days: -12.01%
• 1 month: -53.30%
• 3 months: -52.44%
• 6 months: -46.88%
• Year to date: -61.93%
• 1 year: -57.28%
• 5 years: 39.08%
• 10 years: -32.82%
• Sector: Industrials
• Industry: Management Services

About: Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Employees: 4,700

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

38% more repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 74

3.49% more ownership

Funds ownership: 108.82% [Q1] → 112.31% (+3.49%) [Q2]

3% less funds holding

Funds holding: 250 [Q1] → 243 (-7) [Q2]

13% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 53

39% less capital invested

Capital invested by funds: $4.12B [Q1] → $2.49B (-$1.62B) [Q2]

43% less funds holding in top 10

Funds holding in top 10: 7 [Q1] → 4 (-3) [Q2]

58% less call options, than puts

Call options by funds: $10.5M | Put options by funds: $25.1M

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 26% upside
• Avg. target: $31 144% upside
• High target: $45 255% upside

11 analyst ratings

• positive: 10 91%
• neutral: 1 9%
• negative: 0 0%

Citigroup Daniel Grosslight 57% 1-year accuracy 8 / 14 met price target	66% upside $21	Buy Maintained	13 Nov 2024
RBC Capital Sean Dodge 76% 1-year accuracy 22 / 29 met price target	58% upside $20	Outperform Reiterated	12 Nov 2024
Barclays Stephanie Davis 59% 1-year accuracy 10 / 17 met price target	50% upside $19	Overweight Maintained	11 Nov 2024
Oppenheimer Jeff Jones 39% 1-year accuracy 14 / 36 met price target	168% upside $34	Outperform Maintained	8 Nov 2024
Stephens & Co. Jeff Garro 25% 1-year accuracy 1 / 4 met price target	26% upside $16	Equal-Weight Downgraded	8 Nov 2024